Adapting breast cancer care during COVID-19 pandemic

Pfizer is committed to supporting its NHS colleagues during the COVID-19 pandemic. NHS England has released guidance on the management of cancer patients at this difficult time.2 This guidance provides the following recommendations which we believe we can provide assistance with:

  • Consider dispensing longer periods of oral medications if at all possible, to minimise patient exposure
  • Seek alternative methods to monitor and review patients on systemic therapies

As such, we would like to bring to your attention the availability of our 3-month packaging for IBRANCE® (palbociclib). The 3-month packaging is available in addition to the 1-month packaging and can be ordered via the same process.

The following table provides some further useful information when ordering:




IBRANCE® CAP 125 mg x 63



IBRANCE® CAP 100 mg x 63



IBRANCE® CAP 75 mg x 63



We can confirm that we are not making any changes to the current patient access scheme.

In line with our Summary of Product Characteristics, for patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles, complete blood counts for subsequent cycles should be monitored every 3 months, prior to the beginning of a cycle and as clinically indicated.1 These patients may benefit from the 3-month packaging.

Should you require any help or assistance with necessary coding for the 3-month packaging, please contact our Customer Contact Centre on 0845 608 8866. Alternatively, you can contact your local Pfizer representative.

AI, aromatase inhibitor; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; LHRH, luteinising hormone-releasing hormone.

1. Pfizer. IBRANCE® (palbociclib) Summary of Product Characteristics. December 2019. Available at: (accessed March 2020)
2. NHS England. Clinical guide for the management of noncoronavirus patients requiring acute treatment: Cancer. Publications approval reference: 001559. Available at: (accessed March 2020).

PP-IBR-GBR-2318. April 2020